- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$4,030.56 MnMarket Estimate, 2026
$4,221.61 MnMarket Forecast, 2034
$6,114.75 MnCAGR, 2026–2034
4.74%Executive Summary: North America Alzheimer’s Disease Market
- Market Scope: Comprehensive North American Alzheimer’s disease market analysis covering population aging, neurodegenerative disorder prevalence, anti-amyloid monoclonal antibodies, AI-powered diagnostics, and biomarker-based companion diagnostics.
- Market Valuation: Valued at USD 12.45 billion (2025), estimated at USD 13.66 billion (2026), and projected to reach USD 28.67 billion by 2034, registering a robust CAGR of 9.72% (2026–2034).
- Primary Growth Drivers: Aging demographics, rising neurodegenerative cases, disease-modifying therapy adoption, AI diagnostics integration, and expanding government funding. Key challenges include high treatment costs, limited late-stage therapeutic efficacy, and strict clinical trial regulatory scrutiny.
Key Market Segment Metrics (2026–2034)
| Category | Leading Segment (Position) | Fastest-Growing Segment |
|---|---|---|
| By Treatment, Application & Region | Disease-modifying therapies (largest treatment segment due to FDA approvals and Medicare expansions) & Diagnostic services (dominated application segment) & United States (held largest regional share at 89.4% in 2025) | Blood-based biomarker tests (emerging as the fastest-growing category at an 18.3% CAGR) & Canada (expanding via provincial adoption of novel diagnostics/therapies) |
| By Regional Leadership | United States (89.4% share supported by advanced healthcare infrastructure and Medicare coverage for new therapeutics) | Canada (accounts for remaining share with health systems progressively implementing novel frameworks) |
Major Market Players & Market Structure
Market Structure: Highly competitive, innovation-driven North American biopharmaceutical and diagnostics landscape featuring major enterprise leaders driving anti-amyloid commercialization, monthly-dosed therapy launches, and clinical lab plasma test scaling.
Key Companies: Biogen Inc., Eisai Co. Ltd., Eli Lilly and Company, Roche Holding AG, AbbVie Inc., Johnson & Johnson, Pfizer Inc., Merck & Co. Inc., Avid Radiopharmaceuticals, and Fujirebio Diagnostics.
North America Alzheimer’s Disease Market Size
The North America Alzheimer’s Disease Market is projected to grow from USD 4,030.56 million in 2025 to USD 4,221.61 million in 2026 and reach USD 6,114.75 million by 2034, registering a CAGR of 4.74% from 2026 to 2034.
The growing geriatric population and the increasing ubiquity of Alzheimer's disease are important factors driving the Alzheimer's disease market in North America.
According to the Alzheimer’s Association, in 2023, an estimated 5.4 million Americans of all ages had Alzheimer's disease. One in nine people aged 65 and above has Alzheimer's disease. By 2050, the number of people aged 65 and above affected by Alzheimer's disease is projected to nearly triple, from 5.2 million to an expected 13.8 million. Increasing R&D activity and a strong pipeline of disease-modifying drugs are the crucial factors driving the market growth in this region. Alzheimer's disease is the leading cause of dementia in the elderly, an integral part of the aging process. Hence, the increasing geriatric population globally acts as a key driver for Alzheimer's disease diagnosis and treatment market. The high prevalence of Alzheimer's disease worldwide is a key factor for the market's growth. It stresses the need to improve a successful cure for Alzheimer's disease.
Additionally, factors contributing to the market's growth are increasing the development of online drugs, increasing the incidence and prevalence of Alzheimer's disease, increasing sophisticated diagnostics for early detection and precise drug development, and new emerging diagnostic techniques. Investments in biomarker development for drug development and early detection of Alzheimer's disease are the main drivers and drive the growth of the North American market for Alzheimer's.
The early diagnosis of the indication is a challenge for Alzheimer's disease and is becoming a significant threat to public health due to the growing number of people affected.
This research report on the North America Alzheimer’s disease Market has been segmented and sub-segmented into the following categories
North America Alzheimer’s Disease Market Analysis By Therapeutics
-
Marketed Drugs
-
NMDA Receptor Antagonists
- Cholinesterase Inhibitors
-
- Pipeline Drugs
North America Alzheimer’s Disease Market Analysis By Diagnostics
-
Computed Tomography Scan
-
Electroencephalography
- Lumbar Puncture Test
- Magnetic Resonance Imaging
- Positron Emission Tomography
- Others
North America Alzheimer’s Disease Market Analysis By Country
-
The United States
-
Canada
- Rest of North America
Geographically, North America currently dominates the global market for Alzheimer's disease and is expected to continue strengthening for a few years.
The U.S. holds the largest share of the worldwide market for diagnosing and treating Alzheimer's disease. The United States is the world leader in the intervention and treatment of Alzheimer's disease. The United States has many biopharmaceutical companies, accumulating 86 drugs to fight Alzheimer's disease at different stages. Hence, the market is expected to display a healthy CAGR during the forecast period. According to the Alzheimer's Association, more than 6 million Americans will be living with Alzheimer's disease by 2020. One in nine people aged 60 and over has Alzheimer's disease. By 2040, the number of people aged 60 and over affected by Alzheimer's disease is expected to nearly triple, from 6.2 million to 17.8 million, excluding the development of medical advances to prevent or cure the disease. Death rates from Alzheimer's disease are relatively high. Between 2005 and 2019, deaths from heart disease, stroke, and prostate cancer decreased by 15%, 24%, and 12%, respectively, while deaths from Alzheimer's disease increased by 76%. The United States accounts for a significant share of approximately 86% of total revenues in North America.
On the other hand, the Canadian market is also anticipated to grow at a healthy CAGR during the forecast period owing to the growing incidence of Alzheimer’s in Canada. As per the statistics published by Alzheimer’s Association, an estimated 747,000 Canadians have Alzheimer’s or another dementia.
KEY MARKET PLAYERS
A few of the major players dominating the North American Alzheimer’s disease market are Abbvie Inc., Pfizer Inc., AC Immune SA, Eisai Co Ltd., Allergan PLC, Novartis AG, Amarantus Bioscience Holdings, H. Lundbeck A/S, Anavex LifeSciences, Avid Radiopharmaceuticals, Forest Laboratories Inc., Axon Neuroscience, Daiichi Sankyo Co, TauRx Therapeutics Ltd, Eli Lilly, F. Hoffmann La Roche AG, Johnson & Johnson, GE Healthcare and Janssen Pharmaceuticals.